Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. Chester, C., Chang, S., Kurland, J. F., Sagiv-Barfi, I., Czerwinski, D., Rajapaksa, A., Waller, E., Sadaram, M., Richards, L., Cohen, L. J., Ahlers, C., Jure-Kunkei, M., Maecker, H., Levy, R., Kohrt, H. AMER SOC CLINICAL ONCOLOGY. 2014
View details for Web of Science ID 000358613202908